Trial Profile
Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Renal calculi
- Focus Therapeutic Use
- Sponsors Mayo Clinic
- 28 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Nov 2015 Primary endpoint has been met. (Change in Calcium phosphate SS), as published in the Journal of Urology
- 17 Nov 2015 Primary endpoint has been met. (Change in urinary calcium oxalate supersaturation (SS)), as published in the Journal of Urology